New drug CAY001 enters first human safety trial
NCT ID NCT06845839
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests the safety of a new drug called CAY001 in 24 healthy adults aged 18-50. Participants receive a single dose of the drug or a placebo by IV, and researchers monitor them for 28 days for side effects and how the drug moves through the body. The goal is simply to see if it is safe enough to study further.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CAY001 (a complex of polyphosphate and silica nanoparticles)
- What could go wrong
- This is a very early, first-in-human study with only 24 healthy people. It is designed to check safety, not to treat any disease, so it may not lead to any medical use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
TKL Research
RECRUITINGFair Lawn, New Jersey, 07410, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test